Joseph Balthasar, Abceutics founder
Merck signs small acquisition to make ADCs safer
Antibody-drug conjugates have caught the biopharma world by storm, and Merck has been an active dealmaker in the space via multibillion-dollar pacts
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
